According to the research report titled ‘Atrial Fibrillation Drugs Market Size By Products (Antiarrhythmic Drugs, Anticoagulant Drugs {Vitamin K Antagonists, Novel Oral Anticoagulants [Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors]}), By Atrial Fibrillation Type (Paroxysmal, Persistent, Permanent), By Application (Heart Rhythm Control, Heart Rate Control) By Route of Administration (Oral, Injectable) By End-use (Hospitals, Cardiac Centres, Ambulatory Surgical Centres) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Poland, Switzerland, Belgium, Czech Republic, Netherlands, Sweden, Hungary, Austria, Portugal, Denmark, Norway, Finland, Ireland, Turkey, Greece, China, Japan, India, Australia, South Korea, Taiwan, New Zealand, Singapore, Brazil, Argentina, Venezuela, Columbia, Mexico, South Africa, Saudi Arabia, UAE, Egypt), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025’, available at MarketStudyReport.com, the global atrial fibrillation drugs market is expected to surpass USD 17 billion by the year 2025.
 

According to the report, increased pervasiveness of valvular diseases coupled with growing elderly population is a major factor driving the atrial fibrillation drugs market growth. Rising adoption of sedentary lifestyle and unhealthy eating habits among millennial population is also positively impacting the demand for atrial fibrillation drugs across the globe. However, adverse side effects such as tiredness, severe bleeding may hinder the market growth. Moreover, scarcity of awareness pertaining to treating options for atrial fibrillation in emerging economies may further inhibit the market growth.
 

As per product type, the report states that anticoagulant drugs market segment is expected to grow by 3.5% by the year 2025. Anticoagulants facilitate in reducing the risk of stroke in patients suffering from atrial fibrillation. Thus, high demand of anticoagulants to treat atrial fibrillation along with surging investments towards development of therapeutic drugs are aiding the market growth.
 

In terms of atrial fibrillation type, the paroxysmal segment held USD 7,095.8 million in the year 2018 and is presumed to expand significantly during the estimated timeframe. Rising prevalence of paroxysmal atrial fibrillation along with growing geriatric population are fueling the segmental growth.
 

By route of administration, the report cites that the injectable atrial fibrillation drugs market is expected to grow with a CAGR of 2.4% during the period of 2019-2025. Patients suffering from atrial fibrillation are prohibited from taking drugs orally and thus, increasing usage of injectables are stimulating the industry outlook.
 

Citing the end-use segmentation, the hospitals segment was valued at USD 6, 583.2 million in the year 2018. Easy availability of drug therapies coupled with increasing collaborations among market majors and hospitals has led to shifting preferences towards hospitals for treating atrial fibrillation, hence favoring the market outlook.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2057027/
 

Considering the geographical landscape, the report states that the atrial fibrillation drugs industry in U.S. is presumed to expand with a CAGR of 2.4% between 2019 and 2025. High presence of key industry players and high occurrence rate of chronic diseases such as hypertension and diabetes are augmenting the demand for atrial fibrillation drugs in U.S. On the other hand, atrial fibrillation drugs market in China was worth USD 805.4 million in 2018 and is estimated to witness consistent growth in the subsequent years. Increasing popularity of private clinics along with rising development of multi-specialty hospitals are contributing towards the market growth.
 

The prominent companies operating in the atrial fibrillation drugs market are Sanofi, Portola Pharmaceuticals, Pfizer, Mitsubishi Tanabe Pharma, Johnson & Johnson (JanssenOrtho), GlaxoSmithKline, Daiichi Sankyo, Bristol-Myers Squibb, Boehringer Ingelheim, and AstraZeneca.